<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137994</url>
  </required_header>
  <id_info>
    <org_study_id>113333</org_study_id>
    <nct_id>NCT01137994</nct_id>
  </id_info>
  <brief_title>A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, open-label, multi-center study evaluating the efficacy and&#xD;
      safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with&#xD;
      chemotherapy in women with HER2-positive and p95HER2-positive metastatic breast cancer (MBC).&#xD;
      Eligible subjects will have newly diagnosed metastatic breast cancer (Stage IV) either as a&#xD;
      primary diagnosis or as a recurrence following treatment of curative intent; not have&#xD;
      received systemic or local treatment for MBC and have breast cancer that is positive for HER2&#xD;
      and p95HER2. The primary objective is to compare progression-free survival (PFS) of lapatinib&#xD;
      plus chemotherapy versus trastuzumab plus chemotherapy as first-line treatment in subjects&#xD;
      with MBC exhibiting concurrent HER2 overexpression (and/or gene amplification) and expression&#xD;
      of carboxy-terminal fragments of HER2 (p95HER2). The secondary objectives are to evaluate&#xD;
      overall survival, overall response rate, clinical benefit response rate and the safety as&#xD;
      well as tolerability of lapatinib plus chemotherapy and trastuzumab plus chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from randomization to disease progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR: complete response [CR] or partial response [PR])</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit response rate (CBR: CR or PR at any time, or stable disease [SD] &gt;=24 weeks</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of lapatinib plus chemotherapy and trastuzumab plus chemotherapy</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neoplasms, Breast</condition>
  <arm_group>
    <arm_group_label>Lapatinib plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor</description>
    <arm_group_label>Lapatinib plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>monoclonal antibody directed to HER2 receptor</description>
    <arm_group_label>Trastuzumab plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Taxane chemotherapy</description>
    <arm_group_label>Lapatinib plus Chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Taxane chemotherapy</description>
    <arm_group_label>Lapatinib plus Chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinka alkaloid</description>
    <arm_group_label>Lapatinib plus Chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab plus Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female ≥ 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer with distant&#xD;
             metastasis(ses) (designated as Stage IV or metastatic breast cancer)&#xD;
&#xD;
               -  Diagnosis with Stage IV or metastatic disease at either primary diagnosis or&#xD;
                  recurrence&#xD;
&#xD;
          -  Not received prior systemic or local treatment (e.g., chemotherapy, endocrine or&#xD;
             radiotherapy) for Stage IV/metastatic breast cancer&#xD;
&#xD;
               -  Prior adjuvant and/or neo-adjuvant therapy is permitted&#xD;
&#xD;
          -  Documentation of HER2 overexpression or gene amplification, in the invasive component&#xD;
             of either a metastatic disease site or primary tumor, defined as: 3+ by IHC and/or&#xD;
             HER2/neu gene amplification by fluorescence, chromogenic or silver in situ&#xD;
             hybridization [FISH, CISH or SISH; &gt;6 HER2/neu gene copies per nucleus or a FISH, CISH&#xD;
             or SISH test ratio (HER2 gene copies to chromosome 17 signals) of ≥2.0]&#xD;
&#xD;
          -  Documentation by the central laboratory of positive p95HER2 expression in the invasive&#xD;
             component of either a metastatic disease site (preferred) or primary tumor&#xD;
&#xD;
          -  No history of CNS metastases (including leptomeningeal involvement) or stable CNS&#xD;
             metastases (defined as asymptomatic and off steroids for ≥ 3 months)&#xD;
&#xD;
          -  Baseline Left Ventricular Ejection Fraction (LVEF) ≥50% measured by echocardiography&#xD;
             (ECHO) or multi-gated acquisition scan (MUGA)&#xD;
&#xD;
          -  Recovered or stabilized from all adverse events associated with prior anti-cancer&#xD;
             therapies, including radiotherapy, at the time of screening&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2&#xD;
&#xD;
          -  Have adequate marrow and organ function as defined as:&#xD;
&#xD;
        SYSTEM LABORATORY VALUES Hematologic ANC ≥1.5 x 109/L Hemoglobin ≥9 g/dL (after transfusion&#xD;
        if needed) Platelets ≥100 x 109/L Hepatic Albumin ≥ 2.5 g/dL Serum bilirubin ≤1.5 x ULN&#xD;
        unless due to Gilbert's syndrome AST and ALT ≤3 x ULN Renal Calculated creatinine clearance&#xD;
        ≥ 40 mL/min Serum Creatinine ≤1.5 mg/dL or 132.6µmol/L (Abbreviations: ANC, absolute&#xD;
        neutrophil count; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine&#xD;
        aminotransferase)&#xD;
&#xD;
          -  Women of childbearing potential, including women whose last menstrual period was &lt;12&#xD;
             months ago (unless surgically sterile) must have a negative serum pregnancy test and&#xD;
             agree to use effective contraception, as defined in protocol&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancy. Exception: Subjects who have been disease-free for 5&#xD;
             years or subjects with a history of completely resected non-melanoma skin cancer&#xD;
             (basal or squamous) are eligible&#xD;
&#xD;
          -  Concurrent anti-cancer treatment or concurrent treatment with an investigational drug&#xD;
&#xD;
          -  Administration of an investigational drug within 30 days or 5 half-lives, whichever is&#xD;
             longer, preceding the first dose of study treatment&#xD;
&#xD;
          -  Prior treatment with anti-HER2 therapy, except trastuzumab or lapatinib (time from&#xD;
             last dose of trastuzumab or lapatinib to randomization must be ≥3 months)&#xD;
&#xD;
          -  Serious cardiac illness or medical condition including but not confined to:&#xD;
&#xD;
               -  Uncontrolled arrhythmias&#xD;
&#xD;
               -  Uncontrolled or symptomatic angina&#xD;
&#xD;
               -  History of congestive heart failure (CHF)&#xD;
&#xD;
               -  Documented myocardial infarction &lt;6 months from study entry&#xD;
&#xD;
          -  Current active hepatic or biliary disease (with exception of Gilbert's syndrome,&#xD;
             asymptomatic gallstones, liver metastases or stable chronic liver disease per&#xD;
             investigator assessment)&#xD;
&#xD;
          -  Concurrent disease or condition, or any pre-existing medical disorder that in the&#xD;
             opinion of the investigator may interfere with the subject's safety, obtaining&#xD;
             informed consent or compliance to the study procedures&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Any clinically significant gastrointestinal abnormalities that may alter absorption&#xD;
             such as malabsorption syndrome or major resection of the stomach or bowels (consult&#xD;
             with GSK Medical Monitor if uncertain about eligibility)&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to any of the study drugs or their excipients that, in the opinion&#xD;
             of the investigator contra-indicates participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ErbB2</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>p95HER2</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>HER2</keyword>
  <keyword>Lapatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

